Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by Algert Global LLC

Algert Global LLC increased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 25.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,642 shares of the company’s stock after purchasing an additional 4,170 shares during the quarter. Algert Global LLC’s holdings in Omnicell were worth $919,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Omnicell by 93.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after buying an additional 699,925 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock valued at $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after purchasing an additional 377,883 shares during the period. Oberweis Asset Management Inc. purchased a new stake in shares of Omnicell during the fourth quarter worth about $14,834,000. Finally, Renaissance Technologies LLC raised its position in shares of Omnicell by 79.3% during the 4th quarter. Renaissance Technologies LLC now owns 456,343 shares of the company’s stock worth $20,316,000 after purchasing an additional 201,831 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Up 1.9 %

Shares of OMCL opened at $25.88 on Friday. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $32.28 and a two-hundred day simple moving average of $39.96. The company has a market capitalization of $1.21 billion, a PE ratio of 95.86, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Omnicell’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 earnings per share. As a group, equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Upgrades and Downgrades

OMCL has been the subject of several research reports. Benchmark cut their price objective on Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, May 3rd. Wells Fargo & Company lowered their target price on shares of Omnicell from $38.00 to $31.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, JPMorgan Chase & Co. dropped their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $45.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.